orelabrutinib   Click here for help

GtoPdb Ligand ID: 10629

Synonyms: example 3 [WO2015048662A2] | ICP-022 | ICP022
Approved drug Immunopharmacology Ligand
orelabrutinib is an approved drug (China (2020))
Compound class: Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN orelabrutinib, is identical to the structure of example 3 that is claimed as a BTK inhibitor in patent WO2015048662A2 [2]. The inhibitors in WO2015048662A2 are claimed for their potential to treat cancers [1] and inflammatory/autoimmune diseases that are mediated, at least in part, by Bruton's tyrosine kinase (BTK). Innocare Pharma have declared the ICP-022>orelabrutinib association on their company news webpage. Orelabrutinib is an orally administered, potent, irreversible and selective BTK-inhibitor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 85.52
Molecular weight 427.19
XLogP 3.62
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)N1CCC(CC1)c1ccc(c(n1)c1ccc(cc1)Oc1ccccc1)C(=O)N
Isomeric SMILES C=CC(=O)N1CCC(CC1)c1ccc(c(n1)c1ccc(cc1)Oc1ccccc1)C(=O)N
InChI InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
No information available.
Summary of Clinical Use Click here for help
Orelabrutinib (ICP-022) has advanced to Phase 2 evaluation in patients with relapsed/refractory marginal zone lymphoma (MZL). It is also being investigated in other B cell malignancies. Click here to link to ClinicalTrials.gov's full list of ICP-022 studies. China granted approval in December 2020, for the treatment of previously treated mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) [3]. FDA orphan designation for MCL was also issued in December 2020. In February 2021 the Chinese approval was expanded to include use as a first-line MCL therapy in combination with R-CHOP chemotherapy.
In July 2021 it was revealed that Biogen will be partnering with InnoCare to investigate orelabrutinib's potential in relapsing/remitting multiple sclerosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04438005 A Study of ICP-022 in Patients With R/R DLBCL Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.
NCT03494179 A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) Phase 1/Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.
NCT04578613 ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL Phase 3 Interventional Beijing InnoCare Pharma Tech Co., Ltd.
NCT04305197 A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.
NCT04831658 A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma Phase 4 Interventional Zhengzhou University
NCT04711148 A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis Phase 2 Interventional Beijing InnoCare Pharma Tech Co., Ltd.